| pubmed-article:21506127 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0079744 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0205219 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:21506127 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:21506127 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21506127 | pubmed:dateCreated | 2011-6-7 | lld:pubmed |
| pubmed-article:21506127 | pubmed:abstractText | NF-?B is frequently over-expressed in a variety of non-Hodgkin's lymphomas (NHLs) and has been implicated in lymphomagenesis; however, its role in diffuse large B cell lymphoma (DLBCL) as a prognostic biomarker has not been fully elucidated. Therefore, we investigated the role of NF-?B and its association with clinicopathological features in a tissue microarray cohort of 230 DLBCL patient samples. We then elucidated the role of NF-?B inhibition on cell viability and apoptosis in vitro, using DLBCL cell lines. Using immunohistochemistry, NF-?B was detected in 25.6% (52/203) DLBCL tumours, was associated with activated B cell (ABC) phenotype (p = 0.0054), Epstein-Barr virus (EBV; p = 0.0080) and over-expression of the anti-apoptotic marker XIAP (p = 0.0013). DLBCL cases with nuclear expression of NF-?B showed a significantly poorer overall survival as compared to those without NF-?B expression (p = 0.0236). In a multivariate analysis using a Cox proportional hazard model for IPI and NF-?B expression, the relative risk was 2.97 for high NF-?B expression (95% CI 1.27-6.94; p = 0.0113) and 7.55 for the high-IPI group (95% CI 3.34-18.35; p < 0.0001). In vitro, Bay 11-7085 inhibited constitutively active NF-?B expression in a dose-dependent manner and inhibition of NF-?B also down-regulated expression of the downstream target gene products Bcl-2, Bcl-XL (BCL2L1), XIAP and Survivin, leading to apoptosis via activation of the mitochondrial apoptotic pathway. NF-?B over-expression was found to be an independent prognostic marker for poor survival in DLBCL. Altogether, these results suggest that NF-?B may be a useful prognostic biomarker and a potential target for therapeutic intervention in DLBCL. | lld:pubmed |
| pubmed-article:21506127 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21506127 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21506127 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21506127 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21506127 | pubmed:issn | 1096-9896 | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:UddinShahabS | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:AjarimDahishD | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:AhmedMaqboolM | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:BuRongR | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:AbubakerJehad... | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:Al-DayelFouad... | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:Al-KurayaKhaw... | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:HussainAzhar... | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:BaviPrashantP | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:QadriZeeshanZ | lld:pubmed |
| pubmed-article:21506127 | pubmed:author | pubmed-author:BaldeValorieV | lld:pubmed |
| pubmed-article:21506127 | pubmed:copyrightInfo | Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:21506127 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21506127 | pubmed:volume | 224 | lld:pubmed |
| pubmed-article:21506127 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21506127 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21506127 | pubmed:pagination | 355-66 | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:meshHeading | pubmed-meshheading:21506127... | lld:pubmed |
| pubmed-article:21506127 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21506127 | pubmed:articleTitle | The biological and clinical impact of inhibition of NF-?B-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). | lld:pubmed |
| pubmed-article:21506127 | pubmed:affiliation | Human Cancer Genomic Research, Research Center, King Fahad National Center for Children's Cancer, Riyadh, Saudi Arabia. | lld:pubmed |
| pubmed-article:21506127 | pubmed:publicationType | Journal Article | lld:pubmed |
